RIN3

RIN3 is a multidomain guanine nucleotide exchange factor (GEF) that activates the early-endosomal small GTPases RAB5 and RAB31 to drive membrane trafficking (PMID:12972505, PMID:21586568). It localizes to cytoplasmic RAB5-positive vesicles distinct from EEA1 compartments and routes a portion of internalized transferrin to early endosomes (PMID:12972505), with its RIN-unique RH domain forming the RAB5-binding region required for catalysis (PMID:18486601). RIN3 activity is gated by upstream signaling: tyrosine-phosphorylation events translocate RIN3 to RAB5-positive vesicles, and engagement of activated Ras with its inhibitory RA domain promotes the active conformation (PMID:18486601). Its Rab31-GEF activity, which is genetically separable from its Rab5-GEF function, supports redistribution of the cation-dependent mannose-6-phosphate receptor from the trans-Golgi network to peripheral vesicles (PMID:21586568). Through its proline-rich domain, RIN3 binds the SH3 domains of the endocytic adaptors BIN1/amphiphysin and CD2AP and recruits them onto RAB5-positive endosomes (PMID:12972505, PMID:26296892, PMID:32552912), with high-resolution structures defining the CD2AP SH3-1/SH3-2 docking sites (PMID:26296892); BIN1 acts as a critical brake whose loss—via Rin3 knockout or familial Alzheimer's disease RIN3 missense mutations in the BIN1-binding domain—causes RAB5 hyperactivation and endosomal enlargement (PMID:41604486). In specialized cell contexts RIN3 operates downstream of KIT/SCF signaling as a negative regulator of KIT endocytosis and mast cell migration (PMID:23185384), modulates APP endocytosis and amyloid-β generation by sequestering the neuronal BIN1V1 isoform to spatially separate APP from BACE1 (PMID:32552912, PMID:35241726), and negatively regulates osteoclast-mediated bone resorption in vivo (PMID:33725152).

1. 2003 High

   Established RIN3's core biochemical identity by showing it is a GEF that loads and stabilizes GTP onto Rab5 and resides on a distinct early-endocytic vesicle population, defining it as a trafficking regulator.

   Evidence Cell-free GEF assay, immunofluorescence co-localization, and transferrin trafficking in HeLa cells

   PMID:12972505

   Open questions at the time

   • Did not define how RIN3 GEF activity is regulated in cells
   • RAB5 effector consequences downstream of activation not addressed
2. 2003 Medium

   Identified the first SH3-domain partner, showing RIN3's proline-rich domain recruits amphiphysin II onto RIN3/Rab5 vesicles and linking RIN3 to the endocytic adaptor machinery.

   Evidence Co-IP, domain mapping, and co-expression/co-localization in HeLa cells

   PMID:12972505

   Open questions at the time

   • Functional consequence of amphiphysin recruitment not established
   • Single-lab interaction without orthogonal binding affinity measurement
3. 2008 Medium

   Defined the activation logic of RIN3, showing tyrosine-phosphorylation triggers vesicular translocation and that Ras engagement with the inhibitory RA domain relieves autoinhibition while the RH domain mediates Rab5 binding.

   Evidence Pervanadate treatment and domain-deletion mutagenesis with immunofluorescence in HeLa cells

   PMID:18486601

   Open questions at the time

   • Direct kinase responsible for RIN3 phosphorylation not identified
   • Physiological upstream signal in native cells not demonstrated
4. 2011 High

   Expanded RIN3 substrate range to Rab31 and demonstrated catalytic separability, showing distinct residues control Rab31 versus Rab5 activation and that Rab31-GEF activity drives CD-MPR redistribution from the TGN.

   Evidence Cell-free and cell-based GEF assays, site-directed mutagenesis, and CD-MPR imaging in HeLa cells

   PMID:21586568

   Open questions at the time

   • Physiological context distinguishing Rab5 versus Rab31 usage unclear
   • CD-MPR cargo consequence (e.g., lysosomal enzyme sorting) not measured
5. 2012 High

   Placed RIN3 in a receptor signaling pathway, showing it acts downstream of KIT/SCF as a Rab5-GEF and negatively regulates KIT internalization and mast cell migration.

   Evidence RIN3 knockdown/overexpression, GTP-Rab5 pull-down, KIT internalization and migration assays in mast cells

   PMID:23185384

   Open questions at the time

   • Mechanism linking RIN3-BIN2 dissociation to KIT trafficking not fully resolved
   • Whether Rab31 contributes in this context untested
6. 2015 High

   Resolved the molecular basis of RIN3 adaptor recruitment, mapping two proline-rich epitopes to CD2AP SH3-1/SH3-2 at atomic resolution and showing RIN3 recruits CD2AP to RAB5a endosomes.

   Evidence Peptide array, Co-IP, ITC, X-ray crystallography (1.65 Å, 1.11 Å), and co-localization

   PMID:26296892

   Open questions at the time

   • Functional role of CD2AP recruitment in trafficking not established
   • Competition between CD2AP and BIN1 for RIN3 not examined
7. 2020 High

   Linked RIN3 to neurodegeneration-relevant trafficking, showing RIN3 recruits BIN1 and CD2AP to endosomes and promotes APP cleavage and Tau phosphorylation through a Rab5-dependent pathway.

   Evidence Co-IP, MS interactomics, Y2H, APP CTF western, axonal transport imaging, and dominant-negative Rab5 rescue in PC12 and primary BFCNs

   PMID:32552912

   Open questions at the time

   • Direct mechanism connecting Rab5 activation to APP processing not detailed
   • In vivo relevance to disease not yet tested at this stage
8. 2022 High

   Defined isoform-specific control of amyloidogenesis, showing RIN3 sequesters neuronal BIN1V1 to delay APP (not BACE1) endocytosis, spatially separating the two and reducing Aβ generation.

   Evidence Confocal microscopy, FACS enrichment, Aβ ELISA, biotinylated APP internalization, and APP processing western blots

   PMID:35241726

   Open questions at the time

   • Precise CLAP-domain contribution to sequestration not biochemically proven
   • Generalizability beyond the studied neuronal model unaddressed
9. 2021 Medium

   Provided in vivo loss-of-function evidence that RIN3 negatively regulates bone resorption, showing Rin3 knockout increases trabecular bone mass via reduced osteoclast surface.

   Evidence Constitutive Rin3 knockout mice, micro-CT, and bone histomorphometry

   PMID:33725152

   Open questions at the time

   • Molecular mechanism in osteoclasts not defined
   • Whether the effect is cell-autonomous to osteoclasts not resolved
10. 2026 High

    Established BIN1 as the critical brake on RIN3 and connected RIN3 to familial Alzheimer's disease, showing that disrupting BIN1-RIN3 binding by knockout or AD missense mutations causes RAB5 hyperactivation and endosomal enlargement.

    Evidence Rin3 knockout mice, CRISPR-edited human iPSC-derived neurons, RAB5 activation assays, endosome size quantification, and transcriptomics

    PMID:41604486

    Open questions at the time

    • Structural basis of how BIN1 binding suppresses GEF activity not resolved
    • Downstream consequences of RAB5 hyperactivation on neuronal survival not fully mapped

• How RIN3's distinct interactions and GEF activities (Rab5 vs Rab31; BIN1 vs CD2AP vs amphiphysin) are coordinately switched across cell types and signaling states remains unresolved.
• No integrated structural model of the autoinhibited versus activated full-length protein
• Identity of the physiological kinase activating RIN3 unknown
• Quantitative rules governing partner selection at the endosome undefined